Brent A. Vaughan

KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA.

Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA.

Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA.

Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999.

WellnessFX, Inc. provides online nutrition services for improving personal health. Its services include blood tests, phone consultations with health practitioners and intuitive online data tracking to measure cardiovascular, metabolic, hormonal and nutritional needs for health. The company was founded by Jim Kean and Brent Vaughan in 2010 and is headquartered in San Francisco, CA.

Cognoa, Inc. offers a mobile application and proprietary algorithm to enable early detection of autism. The firm is a consumer healthcare company that?s changing how parents assess and support their child?s development. The company was founded by Dennis Wall and Brent Vaughan and is headquartered in Palo Alto, CA.

Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020.